9627 related articles for article (PubMed ID: 1667418)
1. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved.
Fouchier F; Pichon J; Forget P
Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315
[TBL] [Abstract][Full Text] [Related]
4. Modifications of the binding properties of the human VIP receptor of IGR39 cells by sulfhydryl reagents.
Fouchier F; Forget P; Pic P; Marvaldi J; Pichon J
Eur J Cell Biol; 1992 Dec; 59(2):382-8. PubMed ID: 1337321
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
6. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
7. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
8. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
[TBL] [Abstract][Full Text] [Related]
9. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture.
Boissard C; Marie JC; Hejblum G; Gespach C; Rosselin G
Cancer Res; 1986 Sep; 46(9):4406-13. PubMed ID: 3015387
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture.
Laburthe M; Rousset M; Chevalier G; Boissard C; Dupont C; Zweibaum A; Rosselin G
Cancer Res; 1980 Jul; 40(7):2529-33. PubMed ID: 6248206
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI).
O'Dorisio MS; Wood CL; Wenger GD; Vassalo LM
J Immunol; 1985 Jun; 134(6):4078-86. PubMed ID: 2985703
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68.
Van Valen F; Jürgens H; Winkelmann W; Keck E
Cell Signal; 1989; 1(5):435-46. PubMed ID: 2561912
[TBL] [Abstract][Full Text] [Related]
14. [Desensitization to VIP by down regulation of its peptide receptors in transformed HT-29 cells of human colonic epithelium in culture].
Boissard C; Hejblum G; Marie JC; Gespach C; Rosselin G
C R Acad Sci III; 1984; 299(19):795-8. PubMed ID: 6099208
[TBL] [Abstract][Full Text] [Related]
15. [Vasoactive intestinal peptide receptor in a human pancreatic carcinoma cell line].
Chen Y
Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):135-7, 12. PubMed ID: 2163737
[TBL] [Abstract][Full Text] [Related]
16. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
17. Combined ultrastructural and biochemical study of cellular processing of vasoactive intestinal peptide and its receptors in human colonic carcinoma cells in culture.
Hejblum G; Gali P; Boissard C; Astesano A; Marie JC; Anteunis A; Hui Bon Hoa D; Rosselin G
Cancer Res; 1988 Nov; 48(21):6201-10. PubMed ID: 2844402
[TBL] [Abstract][Full Text] [Related]
18. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
[TBL] [Abstract][Full Text] [Related]
19. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
Martin JM; Luis J; Marvaldi J; Pichon J; Pic P
Eur J Biochem; 1989 Mar; 180(2):435-9. PubMed ID: 2538331
[TBL] [Abstract][Full Text] [Related]
20. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production.
Du K; Nicole P; Couvineau A; Laburthe M
Biochem Biophys Res Commun; 1997 Jan; 230(2):289-92. PubMed ID: 9016768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]